Immuneering said its pancreatic cancer pipeline is advancing, with new therapies in development and a stronger focus on clinical trials. It also highlighted pre
Immuneering said its pancreatic cancer pipeline is advancing, with new therapies in development and a stronger focus on clinical trials. It also highlighted preclinical atebimetinib data and potential trial access to newer care.
Share this article
📚 More from Billy’s World
Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y •
YouTube: @BankingWithBilly